Enasidenib's innovative therapy offers a new treatment option for AML patients who are unresponsive to or experience relapse with conventional therapies.
Authentic
Guarantee
Fast Delivery
Privacy On November 29, 2018, the U.S. Food and Drug Administration (FDA) warned that symptoms of differentiation syndrome, a life-threatening side effect of ···【More】
Update: 09 Mar,2026Source: BigbearViews: 136
Enasidenib was developed by Celgene in the United States and approved for marketing by the US FDA on August 1, 2017.Enasidenib (English Indicatio···【More】
Update: 09 Mar,2026Source: BigbearViews: 135
Enasidenib is indicated for adult patients with relapsed or refractory acute myeloid leukemia (AML) who have been diagnosed with an isocitrate dehydro···【More】
Update: 09 Mar,2026Source: BigbearViews: 138
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos